Compare JUBILANT LIFE SCIENCES with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES SUN PHARMA JUBILANT LIFE SCIENCES/
SUN PHARMA
 
P/E (TTM) x 15.2 28.7 53.1% View Chart
P/BV x 1.8 2.5 71.7% View Chart
Dividend Yield % 0.8 0.6 130.0%  

Financials

 JUBILANT LIFE SCIENCES   SUN PHARMA
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-19
SUN PHARMA
Mar-19
JUBILANT LIFE SCIENCES/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs898679 132.3%   
Low Rs618375 164.5%   
Sales per share (Unadj.) Rs572.0121.1 472.2%  
Earnings per share (Unadj.) Rs36.213.4 270.8%  
Cash flow per share (Unadj.) Rs59.520.7 287.7%  
Dividends per share (Unadj.) Rs4.502.75 163.6%  
Dividend yield (eoy) %0.60.5 113.8%  
Book value per share (Unadj.) Rs301.9172.6 174.9%  
Shares outstanding (eoy) m159.282,399.26 6.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.34.4 30.4%   
Avg P/E ratio x20.939.4 53.1%  
P/CF ratio (eoy) x12.725.5 50.0%  
Price / Book Value ratio x2.53.1 82.2%  
Dividend payout %12.420.6 60.4%   
Avg Mkt Cap Rs m120,6941,264,650 9.5%   
No. of employees `0002.417.5 13.7%   
Total wages/salary Rs m19,26059,671 32.3%   
Avg. sales/employee Rs Th38,120.616,608.1 229.5%   
Avg. wages/employee Rs Th8,058.43,409.6 236.3%   
Avg. net profit/employee Rs Th2,414.31,833.8 131.7%   
INCOME DATA
Net Sales Rs m91,108290,659 31.3%  
Other income Rs m35710,255 3.5%   
Total revenues Rs m91,466300,914 30.4%   
Gross profit Rs m17,39063,076 27.6%  
Depreciation Rs m3,70917,533 21.2%   
Interest Rs m2,1985,553 39.6%   
Profit before tax Rs m11,84050,246 23.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-2,802-12,144 23.1%   
Tax Rs m3,2686,009 54.4%   
Profit after tax Rs m5,77032,093 18.0%  
Gross profit margin %19.121.7 88.0%  
Effective tax rate %27.612.0 230.8%   
Net profit margin %6.311.0 57.4%  
BALANCE SHEET DATA
Current assets Rs m45,848310,692 14.8%   
Current liabilities Rs m20,897173,396 12.1%   
Net working cap to sales %27.447.2 58.0%  
Current ratio x2.21.8 122.4%  
Inventory Days Days5799 57.3%  
Debtors Days Days51112 45.7%  
Net fixed assets Rs m65,498232,477 28.2%   
Share capital Rs m1592,399 6.6%   
"Free" reserves Rs m47,930411,691 11.6%   
Net worth Rs m48,089414,091 11.6%   
Long term debt Rs m42,42915,226 278.7%   
Total assets Rs m114,685646,938 17.7%  
Interest coverage x6.410.0 63.6%   
Debt to equity ratio x0.90 2,399.5%  
Sales to assets ratio x0.80.4 176.8%   
Return on assets %6.95.8 119.4%  
Return on equity %12.07.8 154.8%  
Return on capital %12.410.2 122.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,42266,025 18.8%   
Fx outflow Rs m17,22738,610 44.6%   
Net fx Rs m-4,80527,415 -17.5%   
CASH FLOW
From Operations Rs m11,21521,965 51.1%  
From Investments Rs m-10,118-6,813 148.5%  
From Financial Activity Rs m6,574-27,305 -24.1%  
Net Cashflow Rs m7,612-8,442 -90.2%  

Share Holding

Indian Promoters % 45.6 63.7 71.6%  
Foreign collaborators % 3.5 0.0 -  
Indian inst/Mut Fund % 8.7 5.1 169.6%  
FIIs % 21.2 23.0 92.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 8.3 254.2%  
Shareholders   23,815 133,026 17.9%  
Pledged promoter(s) holding % 15.9 0.5 2,990.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   ORCHID PHARMA LTD  WYETH LTD  ABBOTT INDIA  UNICHEM LAB  DR. REDDYS LAB  

Compare JUBILANT LIFE SCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Oil & Gas and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended lower. At the closing bell, the BSE Sensex stood lower by 262 points (down 0.7%).

Related Views on News

JUBILANT LIFE SCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of JUBILANT LIFE SCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of JUBILANT LIFE SCIENCES. Also includes updates on the valuation of JUBILANT LIFE SCIENCES.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY20); Net Profit Down 7.7% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 7.7% YoY). Sales on the other hand came in at Rs 22 bn (up 5.0% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Sep 16, 2019 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES - ORCHID PHARMA LTD COMPARISON

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS